132 related articles for article (PubMed ID: 24351446)
1. First symptoms and their age of onset in macular telangiectasia type 2.
Heeren TF; Holz FG; Charbel Issa P
Retina; 2014 May; 34(5):916-9. PubMed ID: 24351446
[TBL] [Abstract][Full Text] [Related]
2. VERY EARLY DISEASE MANIFESTATIONS OF MACULAR TELANGIECTASIA TYPE 2.
Charbel Issa P; Heeren TF; Kupitz EH; Holz FG; Berendschot TT
Retina; 2016 Mar; 36(3):524-34. PubMed ID: 26618805
[TBL] [Abstract][Full Text] [Related]
3. Type 2 idiopathic macular telangiectasia.
Shukla D; Gupta SR; Neelakantan N; Tiwari S; Gupta S; Patwardhan AR; Soubhya TB
Retina; 2012 Feb; 32(2):265-74. PubMed ID: 21968508
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
[TBL] [Abstract][Full Text] [Related]
5. Optical coherence tomographic angiography in type 1 idiopathic macular telangiectasia.
Pappuru RR; Peguda HK; Dave VP
Clin Exp Optom; 2018 Jan; 101(1):143-144. PubMed ID: 28295586
[No Abstract] [Full Text] [Related]
6. Associations between autofluorescence abnormalities and visual acuity in idiopathic macular telangiectasia type 2: MacTel project report number 5.
Balaskas K; Leung I; Sallo FB; Clemons TE; Bird AC; Peto T
Retina; 2014 Aug; 34(8):1630-6. PubMed ID: 24743635
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cone pathologic changes in idiopathic macular telangiectasia types 1 and 2 using adaptive optics scanning laser ophthalmoscopy.
Ooto S; Hangai M; Takayama K; Ueda-Arakawa N; Tsujikawa A; Yamashiro K; Oishi A; Hanebuchi M; Yoshimura N
Am J Ophthalmol; 2013 Jun; 155(6):1045-1057.e4. PubMed ID: 23465268
[TBL] [Abstract][Full Text] [Related]
8. Retinal structural alterations and macular sensitivity in idiopathic macular telangiectasia type 1.
Takayama K; Ooto S; Tamura H; Yamashiro K; Otani A; Tsujikawa A; Yoshimura N
Retina; 2012 Oct; 32(9):1973-80. PubMed ID: 22487581
[TBL] [Abstract][Full Text] [Related]
9. Progressive changes from idiopathic macular telangiectasia seen with spectral domain optical coherence tomography.
Fallano KA; Ibrahim M; Nguyen QD; Do DV
Can J Ophthalmol; 2010 Dec; 45(6):649-50. PubMed ID: 20648067
[No Abstract] [Full Text] [Related]
10. Documentation of Spontaneous Macular Hole Closure in Macular Telangiectasia Type 2 Using Multimodal Imaging.
Balaratnasingam C; Dansingani K; Dhrami-Gavazi E; Yu S; Freund KB; Yannuzzi LA
Ophthalmic Surg Lasers Imaging Retina; 2015 Sep; 46(8):883-6. PubMed ID: 26431306
[TBL] [Abstract][Full Text] [Related]
11. Visual function in patients with idiopathic macular telangiectasia type 1.
Sugiura Y; Okamoto F; Okamoto Y; Hiraoka T; Oshika T
Acta Ophthalmol; 2016 Nov; 94(7):e672-e673. PubMed ID: 27230481
[No Abstract] [Full Text] [Related]
12. Macular Telangiectasia Type 2 Without Clinically Detectable Vasculopathy.
Gillies MC; Mehta H; Bird AC
JAMA Ophthalmol; 2015 Aug; 133(8):951-4. PubMed ID: 26067680
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of photoreceptor mosaic in type 2 idiopathic macular telangiectasia using adaptive optics.
Massamba N; Querques G; Lamory B; Querques L; Souied E; Soubrane G
Acta Ophthalmol; 2011 Nov; 89(7):e601-3. PubMed ID: 20809908
[No Abstract] [Full Text] [Related]
14. Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors.
Chen JJ; Sohn EH; Folk JC; Mahajan VB; Kay CN; Boldt HC; Russell SR
Retina; 2014 Jul; 34(7):1400-6. PubMed ID: 24451922
[TBL] [Abstract][Full Text] [Related]
15. Phakic cystoid macular edema secondary to idiopathic macular telangiectasia type 1 responsive to topical anti-inflammatory agents.
Dunn EN; Gregori NZ; Goldhardt R
Semin Ophthalmol; 2013 Mar; 28(2):84-7. PubMed ID: 23448562
[TBL] [Abstract][Full Text] [Related]
16. Recovery of the neurosensory retina after macular translocation surgery is independent of preoperative macular sensitivity in neovascular age-related macular degeneration.
Mettu PS; Sarin N; Stinnett SS; Toth CA
Retina; 2011 Sep; 31(8):1637-49. PubMed ID: 21775925
[TBL] [Abstract][Full Text] [Related]
17. STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS IN A PATIENT WITH MACULAR TELANGIECTASIA TYPE 2.
Falb T; Malle EM; Haas A; Weger M; Wedrich A
Retin Cases Brief Rep; 2021 May; 15(3):335-338. PubMed ID: 30063580
[TBL] [Abstract][Full Text] [Related]
18. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.
Charbel Issa P; Finger RP; Kruse K; Baumüller S; Scholl HP; Holz FG
Am J Ophthalmol; 2011 May; 151(5):876-886.e1. PubMed ID: 21334595
[TBL] [Abstract][Full Text] [Related]
19. IMPG2-associated retinitis pigmentosa displays relatively early macular involvement.
van Huet RA; Collin RW; Siemiatkowska AM; Klaver CC; Hoyng CB; Simonelli F; Khan MI; Qamar R; Banin E; Cremers FP; Theelen T; den Hollander AI; van den Born LI; Klevering BJ
Invest Ophthalmol Vis Sci; 2014 May; 55(6):3939-53. PubMed ID: 24876279
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia.
Veloso CE; Vianna RN; Pelayes DE; Nehemy MB
Ophthalmic Res; 2013; 49(4):205-8. PubMed ID: 23364325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
